BridgeMD
New treatment option for Stroke
Official title Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
ClinicalTrials.gov ID: NCT02662751
What this study is testing
- What it's testing
- The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 89
You may be able to join if
- The patient was informed about the implementation of the study, its objectives, constraints and patient rights
- The patient has given free and informed consent and signed the consent
- Patient affiliated with or beneficiary of a health insurance plan
- Patient available for 36 months of follow-up
- The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the...
You likely can't join if
- The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an...
- Patient under guardianship or judicial protection
- Refusal to sign the consent
- Inability to correctly inform the patient or his/her trusted person about the study
- The patient is pregnant, parturient, or breastfeeding
- The patient has a contraindication for a treatment used in this study
See the full eligibility criteria
- The patient was informed about the implementation of the study, its objectives, constraints and patient rights
- The patient has given free and informed consent and signed the consent
- Patient affiliated with or beneficiary of a health insurance plan
- Patient available for 36 months of follow-up
- The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage
- The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study.
- Patient under guardianship or judicial protection
- Refusal to sign the consent
- Inability to correctly inform the patient or his/her trusted person about the study
- The patient is pregnant, parturient, or breastfeeding
- The patient has a contraindication for a treatment used in this study
- Known allergy to contrast medium or severe allergy to iodine
- Known active malignancy or history of cancer treatment
- The patient has already undergone a full body scanner in the previous three months
- Renal failure with creatinine clearance below 60 ml / min
- Monoclonal immunoglobulin
- History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
- Emergency situations that hamper the planned course of the study
The study team makes the final eligibility decision.
Where it's taking place
- Montpellier, France
- Nîmes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 89 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montpellier, France; Nîmes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.